Pfizer Inc

• Moderna shares dropped following profit-taking after the recent Analyst Day presentation. • High capital intensity for oncology pivot raised investor concerns over cash burn. • Strong prior stock gains and lack of near-term catalysts triggered selling.

• Summit faced selling pressure ahead of the mid-November ivonescimab regulatory decision. • High cash burn and lack of product revenue weighed on investor sentiment. • SMMT technical indicators show neutral MACD, neutral RSI, and Williams %R sell conditions.

• Johnson & Johnson reported positive clinical trial updates in MedTech and oncology portfolios. • The company exceeded quarterly earnings forecasts and reaffirmed its full-year earnings guidance. • Institutional stakeholders increased their positions amid favorable analyst ratings and technical buy signals.

• Novartis reported strong core earnings per share driven by expanding operating margins. • Management raised full-year core operating income guidance to positive low-single-digit growth. • Technical indicators like MACD and RSI suggest buy conditions for the stock.

• Merck faced profit-taking despite strong third-quarter earnings and upgraded guidance. • Long-term growth concerns persist due to Keytruda's upcoming patent cliff. • Valuation scrutiny and inventory timing adjustments contributed to selling pressure.

• Vertex missed EPS expectations despite higher year-over-year third-quarter revenue. • Operating expenses and Crinetics integration costs pressured third-quarter profitability. • Management raised full-year revenue guidance incorporating the Crinetics acquisition.